1. Australia Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Cleo Diagnostics Ltd

Cleo Diagnostics Ltd

COV.AX
Cleo Diagnostics LtdAU flagAustralian Securities Exchange
0.29
AUD
+0.00
- -
41.29MMarket Cap
Cleo Diagnostics Ltd
COV.AX
(Australian Securities Exchange)

Recent

price

0.29

P/E

ratio

- -

div

yld

- -

ROIC.AI

2023
2024
2025
2026
FRC
- -
- -
- -
- -
Revenue per Share
-0.07
-0.03
-0.03
-0.04
Basic EPS, GAAP
-0.01
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
Dividend per Share
-0.02
0.08
0.05
0.04
Book Value per Share
-0.03
0.08
0.04
0.03
Tangible Book Value per Share
26
117
129
133
Basic Weighted Avg Shares
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
Depreciation Expense
-2
-4
-4
-6
Net Income, GAAP
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
Profit Margin (%)
-1
9
5
5
Working Capital
- -
- -
- -
- -
LT Debt
-1
11
6
5
Total Equity
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
Return on Capital (%)
- -
- -
-48.64
-109.48
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-14.13%
Free Cash Flow
- -
- -
-15.29%
Net Income, GAAP
- -
- -
48.44%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
-0.03
2025
- -
- -
- -
- -
-0.03
2026
- -
- -
- -
- -
-0.04

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Bonraybio Co. Ltd. (6955.TW)
Asensus Surgical, Inc. (ASXC)
Xvivo Perfusion AB (publ) (0RKL.L)
Deltex Medical Group plc (DEMG.L)
LexaGene Holdings Inc. (LXXGF)
Sky Labs Inc. (386380.KQ)
Business
Cleo Diagnostics Ltd, a biotechnology company, engages in the development and patent of a blood test for the detection of ovarian cancer in Australia. The company offers CleoDX pre-surgical triage tests which measures a combination of five biomarkers in serum to provide an accurate determination of malignancy risk prior to surgical referral. It also focuses on developing and testing intellectual property, testing the IP, and securing patents. Cleo Diagnostics Ltd was incorporated in 2021 and is based in Melbourne, Australia.